论文部分内容阅读
由于普通的预测因子不能全面预测结直肠癌的临床结果,因此生物学标志物作为可行的方案正纳入被评估当中。Svagzdys、Lesauskaite、Pangonyte等应用基质金属蛋白酶(MMP-2和MMP-9)及其抑制剂(TIMP-2和TIMP-3)来预测直肠癌患者的生存情况,对64例行直肠癌切除患者的临床病理资料进行回顾性分析。采用半定量计分法对MMP-2、MMP-9、T2MP-2及TIMP-3蛋白表达水平进行测定。在2～96个月(平均48个月)的随访中有28例患者死亡。与存活患者相比,
Because common predictors do not fully predict the clinical outcome of colorectal cancer, biomarkers are being included as a viable option. Svagzdys, Lesauskaite, Pangonyte and other applications of matrix metalloproteinases (MMP-2 and MMP-9) and its inhibitors (TIMP-2 and TIMP-3) to predict the survival of patients with rectal cancer, 64 cases of resected patients with rectal cancer Clinicopathological data were retrospectively analyzed. The expression of MMP-2, MMP-9, T2MP-2 and TIMP-3 protein were determined by semi-quantitative scoring method. In the 2-96 months (mean 48 months) follow-up, 28 patients died. Compared with surviving patients,